Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249899 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 649
- Enrollment target
NCT00249899 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 649 participants.
The verdict
NCT00249899, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 649 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with additional statin therapy on cholesterol levels in treating patients with elevated cholesterol.
Interventions
- DRUG Lapaquistat acetate and stable statin therapy
- DRUG Stable statin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 649 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249899
The ClinicalTrials.gov registry entry for NCT00249899 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 649 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lapaquistat acetate and stable statin therapy is the first listed.
NCT00249899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249899 about?
NCT00249899 is a clinical study titled "Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia". The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with additional statin therapy on cholesterol levels in treating patients with elevated cholesterol.
What is the current status of trial NCT00249899?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 649 participants. The study started on 2005-11. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00249899?
The interventions under investigation include: Lapaquistat acetate and stable statin therapy (DRUG), Stable statin therapy (DRUG).
Who is sponsoring clinical trial NCT00249899?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.